Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
HCB101 in advanced solid tumors and relapsed/refractory non-Hodgkin lymphoma
NCT05892718Phase 1Recruiting
- Sponsor
- FBD Biologics Limited
- Start
- Oct 2023
- Primary completion
- May 2027
- Modality
- Fc-Fusion Proteins
- Countries
- 3
01
Overview
Phase 1, open-label, single-arm trial of HCB-101 in solid tumor (advanced stage) and non-Hodgkin lymphoma (NHL), sponsored by FBD Biologics Limited. Primary endpoints: Adverse Events at 12 months and Maximum Tolerated Dose at 12 months. Started Oct 2023; status: recruiting.
02
Drugs
HCB-101
03
Conditions
solid tumor (advanced stage)non-Hodgkin lymphoma (NHL)
Beyond the preview
Go deeper on NCT05892718.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05892718.